drugset
drugset / Trial / NCT06203457

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

NCT06203457 ↗

Phase 2 Completed 24 enrolled argenx IQVIA Pty Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

Efgartigimod has the potential to improve disease manifestations by the reduction of IgG autoantibodies in Sjogren's Syndrome (SjD or pSS). This open-label extension study will evaluate the long-term safety of efgartigimod in participants with SjD who have completed the treatment period of the qualifying efgartigimod study (ARGX-113-2106).

Timeline

Start
2023-11-29
Primary completion
2025-02-03
Completion
2025-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Efgartigimod Alfa Protein / enzyme biologic 10 mg/kg Intravenous

Indications

Sjogren syndrome